Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 5 | 2018 | 236 | 1.810 |
Why?
|
| Lung Neoplasms | 7 | 2021 | 542 | 1.750 |
Why?
|
| Radiation Oncology | 5 | 2022 | 14 | 1.670 |
Why?
|
| Radiosurgery | 5 | 2018 | 32 | 1.340 |
Why?
|
| Brachytherapy | 2 | 2013 | 44 | 0.770 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 359 | 0.710 |
Why?
|
| Employment | 3 | 2022 | 40 | 0.710 |
Why?
|
| Internship and Residency | 3 | 2022 | 205 | 0.700 |
Why?
|
| Surgical Oncology | 1 | 2020 | 6 | 0.650 |
Why?
|
| Physicians, Women | 1 | 2020 | 15 | 0.640 |
Why?
|
| Medical Oncology | 1 | 2020 | 43 | 0.630 |
Why?
|
| Faculty, Medical | 1 | 2020 | 44 | 0.620 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 123 | 0.600 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 15 | 0.560 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 50 | 0.560 |
Why?
|
| Lymph Nodes | 2 | 2016 | 72 | 0.550 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 135 | 0.550 |
Why?
|
| Pneumonectomy | 1 | 2018 | 76 | 0.540 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 164 | 0.530 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 5 | 0.520 |
Why?
|
| Mycosis Fungoides | 1 | 2016 | 5 | 0.510 |
Why?
|
| Electrons | 1 | 2016 | 16 | 0.510 |
Why?
|
| Radiotherapy | 1 | 2016 | 32 | 0.500 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 68 | 0.480 |
Why?
|
| Radiotherapy Dosage | 4 | 2017 | 93 | 0.460 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 6 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 169 | 0.390 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3783 | 0.380 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 1 | 0.380 |
Why?
|
| Organs at Risk | 1 | 2012 | 7 | 0.380 |
Why?
|
| Humans | 17 | 2022 | 23331 | 0.380 |
Why?
|
| Melanoma | 1 | 2012 | 49 | 0.360 |
Why?
|
| Female | 10 | 2020 | 13124 | 0.320 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 129 | 0.300 |
Why?
|
| Adult | 5 | 2020 | 7070 | 0.290 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 274 | 0.280 |
Why?
|
| United States | 5 | 2022 | 1829 | 0.280 |
Why?
|
| Male | 9 | 2018 | 12629 | 0.270 |
Why?
|
| Aged | 8 | 2022 | 7552 | 0.270 |
Why?
|
| Survival Rate | 2 | 2018 | 323 | 0.250 |
Why?
|
| Middle Aged | 7 | 2018 | 8055 | 0.240 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 87 | 0.240 |
Why?
|
| Tumor Burden | 2 | 2015 | 24 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2018 | 2988 | 0.220 |
Why?
|
| Young Adult | 2 | 2018 | 1674 | 0.190 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 171 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2022 | 1523 | 0.160 |
Why?
|
| Leadership | 1 | 2020 | 89 | 0.150 |
Why?
|
| Career Choice | 1 | 2018 | 24 | 0.150 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2018 | 3 | 0.140 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 12 | 0.140 |
Why?
|
| Prognosis | 2 | 2018 | 740 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2018 | 57 | 0.140 |
Why?
|
| Age Distribution | 1 | 2018 | 71 | 0.140 |
Why?
|
| SEER Program | 1 | 2018 | 37 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 94 | 0.140 |
Why?
|
| Professional Practice Location | 1 | 2017 | 2 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2017 | 11 | 0.130 |
Why?
|
| Censuses | 1 | 2017 | 8 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 774 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 90 | 0.130 |
Why?
|
| Patient Safety | 1 | 2017 | 35 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 102 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1441 | 0.130 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 9 | 0.130 |
Why?
|
| Radiometry | 1 | 2016 | 25 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 122 | 0.130 |
Why?
|
| Mediastinum | 1 | 2016 | 6 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 176 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 289 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2016 | 32 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 314 | 0.120 |
Why?
|
| Age Factors | 1 | 2017 | 641 | 0.110 |
Why?
|
| Orbital Pseudotumor | 1 | 2013 | 1 | 0.100 |
Why?
|
| Optic Nerve Glioma | 1 | 2013 | 1 | 0.100 |
Why?
|
| Graves Ophthalmopathy | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 1429 | 0.100 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Meningioma | 1 | 2013 | 15 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 13 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3040 | 0.100 |
Why?
|
| Adolescent | 1 | 2018 | 1916 | 0.100 |
Why?
|
| Macula Lutea | 1 | 2012 | 3 | 0.100 |
Why?
|
| Optic Disk | 1 | 2012 | 3 | 0.100 |
Why?
|
| Retina | 1 | 2012 | 8 | 0.100 |
Why?
|
| Lens, Crystalline | 1 | 2012 | 33 | 0.090 |
Why?
|
| Software | 1 | 2012 | 50 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 48 | 0.090 |
Why?
|
| Equipment Design | 1 | 2012 | 123 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 73 | 0.060 |
Why?
|
| Medicare | 1 | 2022 | 108 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 153 | 0.040 |
Why?
|
| Population Density | 1 | 2018 | 7 | 0.040 |
Why?
|
| Job Application | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cities | 1 | 2018 | 13 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2018 | 26 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2018 | 23 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 235 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 61 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 593 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 35 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 3 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 36 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 384 | 0.020 |
Why?
|